EU/3/14/1399

About

On 16 December 2014, orphan designation (EU/3/14/1399) was granted by the European Commission to Treeway B.V., the Netherlands, for edaravone for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
edaravone
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of first decision
16/12/2014
Outcome
Positive
EU designation number
EU/3/14/1399

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Treeway B.V.
Sevillawag 142
3047 AL Rotterdam
The Netherlands
Tel. +31 10 298 88 88
Fax +31 10 298 88 89
E-mail: info@treeway.nl

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating
Average
1 rating
1 rating